Business
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023
WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023 Canada New...
About this update from Atlas Energy Corp.
[{"type":"text","content":"\n \n \n \n WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Estimated FY 2023 revenues in excess of\n \n $1.3 million\n \n is a record year for the Company\n \n \n \n \n Anticipate closing at least three new partnership development agreements including one for our corticosteroid API program, and one new commercial agreement under an existing partnership development program\n \n \n \n \n FY 2024 revenues are expected to increase by more than 100%, which would be another record year for Willow\n \n \n \n \n \n SUNNYVALE, Calif.\n \n \n ,\n \n \n Jan. 10, 2024\n \n \n /CNW/ - Willow Biosciences Inc. (\"\n \n Willow\n \n \") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable ingredients, is pleased to provide a summary of its successes in 2023 and outline its plans for growth across all aspects of its business in 2024.\n \n \n \n \n \n \n \n \n \n \"2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024. We also generated record revenue growth through partnerships and implemented a successful corporate and operational reorganization to support the future growth of Willow,\" said Dr.\n \n Chris Savile\n \n , Willow's President & CEO. \"In 2024, the Company will capitalize on its platform to bring our exciting corticosteroids program to commercial readiness and identify strategic partners for expansion and acceleration of its pipeline of opportunities.\"\n \n \n \n 2023 Achievements\n \n \n \n \n \n Record revenues in 2023:\n \n Revenues increased approximately 60% to an estimated\n \n $1.3 million\n \n in 2023.\n \n \n \n \n \n Launched BioOxi™ bio-oxidation platform technology:\n \n BioOxi is an AI-driven selective hydroxylation platform that has been proven to remove multi...